Band 6+: The chart below shows how much money five big pharmaceutical companies spent on research in 2012 and 2018 and gives an estimate of the amounts spent in 2022. Describe the data providing an overview of the general trends, reporting the main features, and making comparisons.

The bar chart shows the amount of money different pharmaceutical companies allocated for researches in 2012, 2018 and 2022.

Overall, all the presented companies have a continual growth. Pharm has a steady increase through the years. Even though their research was the most funded in 2012, the situation has completely changed by 2022 and its funds became the smallest out of presented 5 companies. The rest of companies have an incredible rise, especially in 2022, but Novas has grown at a much higher rate, becoming a leader in 2018 and having no decent opponents in 2022.

Pharms’ funds went up from 9 bn in 2012 to 22 bn in 2022. Fleming and Avicenna have a comparable rates, but still Fleming leads during all the years. They have grown from 5 to 31 and from 3 to 23 respectively. Biopharms’ research was the least financed in 2012 but have seen a great rise from almost 0 to 25, which made company top 3 among the presented. Meanwhile, Novas has soared dramatically over the 10 years, going from 4 to 57 bn, increased their investments more than 10 times.